Literature DB >> 29079878

[Yellowish, prominent tumor of the corneal periphery].

M Zimmermann1, J Wasielica-Poslednik2, W Lisch2, N Pfeiffer2, A Gericke2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29079878     DOI： 10.1007/s00347-017-0585-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  14 in total

1.  Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry.

Authors:  Dirk Janssen; Dieter Harms
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

2.  Juvenile xanthogranuloma of the iris managed with superficial radiotherapy.

Authors:  P M MacLeod
Journal:  Clin Radiol       Date:  1986-05       Impact factor: 2.350

3.  Juvenile oculodermal xanthogranuloma.

Authors:  J L Smith; R M Ingram
Journal:  Br J Ophthalmol       Date:  1968-09       Impact factor: 4.638

4.  Adult limbal xanthogranuloma.

Authors:  L M Collum; J Mullaney
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

5.  Juvenile xanthogranuloma.

Authors:  W Cadera; M M Silver; L Burt
Journal:  Can J Ophthalmol       Date:  1983-06       Impact factor: 1.882

6.  The epidemiology, clinical characteristics, histopathology and management of juvenile- and adult-onset corneoscleral limbus xanthogranuloma.

Authors:  G Kontos; S Borooah; A Khan; B W Fleck; S E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-21       Impact factor: 3.117

7.  Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis.

Authors:  Shintaro Nakao; Yasuaki Hata; Muneki Miura; Kousuke Noda; Yusuke N Kimura; Shuhei Kawahara; Takeshi Kita; Toshio Hisatomi; Toru Nakazawa; Yiping Jin; M Reza Dana; Michihiko Kuwano; Mayumi Ono; Tatsuro Ishibashi; Ali Hafezi-Moghadam
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

8.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

Authors:  Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

9.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.

Authors:  Yanyan Koenig; Felix Bock; Folkert Horn; Friedrich Kruse; Katja Straub; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

Review 10.  The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiaoyan Liu; Liang Du; Ni Li
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.